Talphera Inc.
TLPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.74M
Close$
$-0.01
101.9% downside
Current Fair Value
101.9% downsideOvervalued by 101.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.74 Million |
|---|---|
| Enterprise Value | $12.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 0.79 |
| Outstanding Shares | 42,410,711 |
Return
| Return on Equity | -77.13% |
|---|---|
| Return on Assets | -47.27% |
| Return on Invested Capital | -58.65% |
Valuation & Multiples
| P/E Ratio | -2.43 |
|---|---|
| PEG | 170.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 12918.56 |
| Enterprise Value to EBIT | -0.84 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1556▲ 59.00% |
|---|---|
| Total Calls | 94,500▼ 88.88% |
| Total Puts | 109,200▼ 77.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 51.56%▲ 1.22% |
|---|---|
| Total Invested | $16.33M▼ 31.35% |
| Investors Holding | 51▲ 6.00% |
ESG Score
No data
About Talphera Inc.
31,000 employees
CEO: Vincent Angotti acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (kno...